Why Dyax (DYAX) Stock Is Soaring Today

NEW YORK (TheStreet) -- Dyax Corp (DYAX) shares are jumping, up 25% to $8.25, on Tuesday after rival Biocryst (BCRX) reported positive findings in the clinical trial for its hereditary angioedema (HAE) drug BCX416.

Investors have reacted positively to the news as it bodes well for Dyax's alternative HAE treatment DX-2930, which is currently being developed as a prophylactic HAE treatment.

Must ReadWarren Buffett's 25 Favorite Stocks 

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

DYAX Chart

DYAX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Dow Falls Sharply as Trump Calls Off North Korea Summit

Dow Falls Sharply as Trump Calls Off North Korea Summit

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern